The book at hand aims to amend this shortcoming, presenting for the first time a thorough overview on TNF action, mechanisms of anti-TNF therapy, treatment strategies, side effects, monitoring, biosimilars and related issues.

Including state-of-the-art information and research results, this publication will be a valuable source of information and guide clinicians to the optimal treatment decision, improving the quality of life of patients with inflammatory bowel disease.

Moreover, rheumatologists or even dermatologists might also find this book of interest.

Fields of Interest: Gastroenterology; Pharmacology; Immunology; Dermatology, Rheumatology

Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Editors
Gerhard Rogler
Hans Herfarth
Toshifumi Hibi
Ole Haagen Nielsen

The introduction of anti-tumor necrosis factor (TNF) antibodies into the treatment of patients with inflammatory bowel disease about fifteen years ago has dramatically improved the quality of life for patients with severe Crohn’s disease and ulcerative colitis. But despite the fact that this therapeutic approach has been around for quite some time, there has been no comprehensive overview to date.

The book at hand aims to amend this shortcoming, presenting for the first time a thorough overview on TNF action, mechanisms of anti-TNF therapy, treatment strategies, side effects, monitoring, biosimilars and related issues.

Including state-of-the-art information and research results, this publication will be a valuable source of information and guide clinicians to the optimal treatment decision, improving the quality of life of patients with inflammatory bowel disease. Moreover, rheumatologists or even dermatologists might also find this book of interest.

Fields of Interest: Gastroenterology; Pharmacology; Immunology; Dermatology, Rheumatology

Frontiers of Gastrointestinal Research, Vol. 34
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Editors: Rogler, G. (Zurich); Herfarth, H. (Chapel Hill, N.C.); Hibi, T. (Tokyo); Nielsen, O.H. (Copenhagen)
VIII + 240 p., 26 fig., 17 in color, 15 tabs., 2015
CHF 198.00 / EUR 185.00 / USD 233.00 (hard cover)
CHF 238.00 / EUR 222.00 / USD 280.00 (online)
Online versions for institutional purchase
Prices subject to change, VAT not included
EUR price for eurozone countries, USD price for USA and Latin America only

CONTENTS
Preface: Rogler, G. et al.

Physiological Role of TNF in Mucosal Immunology
- The Effect of TNF-α on the Regulation of Epithelial Function in Inflammatory Bowel Disease: Tsuchiya, K.
- Physiological Role of TNF in Mucosal Immunology: Regulation of Macrophage/Dendritic Cell Function: Rivollier, A. et al.
- Physiological Role of TNF in Mucosal Immunology: Regulation of T-Cell Function: Scharl, M.

Pathophysiological Role of TNF in Inflammatory Bowel Disease
- Pathophysiological Role of TNF in Inflammatory Bowel Disease: TNF and Its Impact on Barrier Function: Schumann, M.; Kühl, A.
- Pathophysiological Role of TNF in Inflammatory Bowel Disease: TNF and Its Effect on Innate Immune Defense: Scharl, M.
- TNF and Its Impact on Adaptive Immune Mechanisms and Chronic Inflammation: Siegmund, B.

Mechanism of Action of Anti-TNF Antibodies
- Binding of Membrane-Bound TNF: Atreya, R. et al.
- Apoptosis of T Cells and Monocytes: Kucharzik, T.
- Neutralisation of Soluble Tumor Necrosis Factor: Dreesen, E.; Gils, A.

General Treatment Considerations
- Recommended Screening Procedures before Treatment with Anti-TNF Agents: Maaser, C.
- The Risk of Formation of Neutralizing Antibodies: Clark, J.; Sakuraba, A.
- TNF Antagonist Trough Concentrations and Treatment Efficacy in Inflammatory Bowel Disease: Vande Casteele, N.

Biosimilars
- What Is a Biosimilar? Neri, D.
- Is Extrapolation of Safety and Efficacy Data Possible? Ainsworth, M.
- Potential Concerns and Questions: Rogler, G.

Side Effects of Anti-TNF Therapy
- Psoriasis-Like Lesions and Skin Reactions: Herfarth, H.H. et al.
- The Elicitation of Rheumatic Symptoms at Vascular Sites: Geyer, M.; Müller-Ladner, U.
- Serum Reaction, Lupus-Like Syndrome: Schnitzler, F.

Risks of Anti-TNF Therapy
- Risk of Non-Hematologic Malignancy with Anti-TNF Therapy in Inflammatory Bowel Diseases: Join, A. et al.
- Risk of Lymphoma: Nagahori, M.; Watanabe, M.
- Risk of Serious Infection: Naganuma, M.
- Risk of Post-Operative Infections with Anti-TNF Therapy: Cohen, B.L.

Anti-TNF Therapy in Crohn’s Disease
- Predictor of Treatment Response: Tanaka, H.; Motoya, S.
- Step-Up or Top-Down, Combination with Immunosuppression or Not? Barthel, C.; Stange, E.F.

Anti-TNF Therapy in Ulcerative Colitis
- The ‘Ideal’ Anti-TNF Patient: Indications for Anti-TNF Therapy in Ulcerative Colitis: Hisamatsu, T.
- Predictors of the Treatment Response: Kim, H.J.
- What Is the Right Dosage? Michetti, P.

Anti-TNF Therapy in Special Inflammatory Bowel Disease Situations
- Fistulizing and Strictureing Crohn’s Disease: Schoepfer, A.M.
- Postoperative Anti-TNF Therapy in the Management of Crohn’s Disease: Barrie, A.; Regueiro, M.
- Anti-TNF Therapy for Extraintestinal Manifestations of Inflammatory Bowel Disease: Nielsen, O.H. et al.

Anti-TNF Therapy in Special Situations of the Patient
- Anti-TNF Alpha Agents and Breastfeeding: Al-Sum, H.; Maxwell, C.V.

When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease
- When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease: Predictors of Relapse after Stopping Treatment: Louis, E.
- Treatment Options after Anti-TNF Failure: Kobayashi, T.